Incyte Corporation (INCY)
| Market Cap | 18.73B |
| Revenue (ttm) | 4.81B |
| Net Income (ttm) | 1.19B |
| Shares Out | 196.32M |
| EPS (ttm) | 5.90 |
| PE Ratio | 16.16 |
| Forward PE | 12.86 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,264,426 |
| Open | 95.76 |
| Previous Close | 96.10 |
| Day's Range | 93.54 - 96.00 |
| 52-Week Range | 53.56 - 109.28 |
| Beta | 0.81 |
| Analysts | Buy |
| Price Target | 94.94 (-0.49%) |
| Earnings Date | Oct 28, 2025 |
About INCY
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhib... [Read more]
Financial Performance
In 2024, Incyte's revenue was $4.24 billion, an increase of 14.76% compared to the previous year's $3.70 billion. Earnings were $32.62 million, a decrease of -94.54%.
Financial StatementsAnalyst Summary
According to 21 analysts, the average rating for INCY stock is "Buy." The 12-month stock price target is $94.94, which is a decrease of -0.49% from the latest price.
News
Incyte Announces Change to its Board of Directors
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Change to its Board of Directors.
Calls of the Day: Netflix, Thermo Fisher, Incyte and Shake Shack
The Investment Committee debate the latest Calls of the Day.
Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH2025--Updated Positive Data at ASH 2025 Reinforce the Potential of Incyte's INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in ET.
Incyte Corporation (INCY) Discusses mutCALR Data and Therapeutic Advances in Myeloproliferative Neoplasms at ASH Transcript
Incyte Corporation (INCY) Discusses mutCALR Data and Therapeutic Advances in Myeloproliferative Neoplasms at ASH Transcript
Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH2025--Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with MF Presented at ASH 2...
Incyte's First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH2025--Incyte's First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA.
Incyte: Buy At This Inflection Point
Incyte Corporation's rapid non-Jakafi portfolio growth and strong operating leverage look decent amid still-cheap valuation, supporting attractive risk-reward over the coming quarters ahead. Q3 revenu...
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).
Incyte Corporation (INCY) Presents at Evercore 8th Annual Healthcare Conference Transcript
Incyte Corporation (INCY) Presents at Evercore 8th Annual Healthcare Conference Transcript
Global Vitiligo Foundation Applauds Partnership Between Incyte and Winnie Harlow to Elevate Awareness and Understanding of Vitiligo
MECHANICSBURG, Pa.--(BUSINESS WIRE)--The Global Vitiligo Foundation (GVF) commends the newly announced partnership between Incyte and supermodel and beauty entrepreneur Winnie Harlow, who together are...
Incyte Corporation (INCY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Incyte Corporation (INCY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding.
Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel.
Incyte: This Profitable Biotech Trades Like A Melting Iceberg
Incyte's Jakafi LOE overhang masked a quietly transforming, profitable biotech whose non‑Jakafi portfolio is now compounding fast enough to support a structural rerating, despite 2028 risks. Q3 2025 s...
Incyte: Riding Jakafi, Bracing For Generic Headwinds
Incyte Corporation is undervalued, with high revenue growth, strong margins, and a 12.7% upside to a $115 target price; rated Buy. INCY's Q3 results beat expectations, driven by Jakafi and Opzelura sa...
Incyte to Present at Upcoming Investor Conferences
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of December: Citi's 2025 Global Healthcare Conferenc...
Incyte Corporation (INCY) Presents at Jefferies London Healthcare Conference 2025 Transcript
Incyte Corporation ( INCY) Jefferies London Healthcare Conference 2025 November 18, 2025 6:00 AM EST Company Participants William Meury - CEO, President & Director Pablo Cagnoni - President and Head ...
3 Best Healthcare Stocks: Quant Strong Buys From Goldman's 'Alpha' List
The healthcare sector's renewed momentum offers fertile ground for investors wanting to outperform by picking the best stocks from the broader indexes. Goldman Sachs identified 29 healthcare stocks in...
Incyte Announces Positive CHMP Opinion for Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma (FL)
MORGES, Switzerland--(BUSINESS WIRE)---- $INCY--Incyte Announces Positive CHMP Opinion for Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma (FL).
Incyte Corporation (INCY) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript
Incyte Corporation ( INCY) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 10, 2025 10:00 AM EST Company Participants William Meury - CEO, President & Director Pablo Cagnon...
Incyte's Moments of Clarity Program Expands to Highlight Powerful Patient Stories in Vitiligo and Pediatric Eczema
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte's Moments of Clarity Program Expands to Highlight Powerful Patient Stories in Vitiligo and Pediatric Eczema.
Top Biotech Stocks Riding The Rally
Biotech stocks have rebounded after years of underperformance but remain well below their 2021 highs. Successful drug launches, strong trial results, and falling interest rates have boosted stock pric...
Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH2025--Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting.
4 Best Value And Growth Stocks (Yes, They Can Coexist)
The current market is all about momentum, but investors don't need to buy overpriced high-growth stocks to participate in gains. If you dig deep enough, you can find undervalued stocks with growth pot...
Knight Therapeutics Announces Approval and Launch of MINJUVI® (tafasitamab) in Argentina
MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Labo...